Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment [clinicaltrials:NCT00004584]
Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment [clinicaltrials:NCT00004584]
Bio2RDF identifier
NCT00004584
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00004584
identifiers.org URI
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
The purpose of this stu ...... hat includes
ritonavir.
brief title [clinicaltrials_vocabulary:brief-title]
Safety and Effectiveness of a ...... ve Received Previous Treatment
completion date [clinicaltrials_vocabulary:completion-date]
2002-01-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
This is a three-arm stu ...... eline phenotypic sensitivity.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2000-02-10T00:00:00Z
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
is section 801 [clinicaltrials_vocabulary:is-section-801]
keyword [clinicaltrials_vocabulary:keyword]
Anti-HIV Agents
Dose-Response Relationship, Drug
Drug Therapy, Combination
HIV Protease Inhibitors
Reverse Transcriptase Inhibitors
Saquinavir
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2011-04-28T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00004584
official title [clinicaltrials_vocabulary:official-title]
Safety and Antiviral Efficacy ...... erienced HIV-Infected Subjects
org study id [clinicaltrials_vocabulary:org-study-id]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2002-01-01T00:00:00Z
secondary id [clinicaltrials_vocabulary:secondary-id]
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
1999-12-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2011-04-01T00:00:00Z
identifier
clinicaltrials:NCT00004584
title
Safety and Effectiveness of a ...... ve Received Previous Treatment
@en
type
label
Safety and Effectiveness of a ...... t [clinicaltrials:NCT00004584]
@en